Overview

A Study to Assess the Effect of Food on the Bioavailability of the IGF-1R Inhibitor AXL1717 in Patients With Advanced Malignant Tumors

Status:
Completed

Trial end date:
2013-12-01

Target enrollment:

Participant gender:

Summary

This is a prospective, randomized, open-label, Phase I, crossover study to assess the effect of food on the bioavailability of AXL1717 including patients with advanced malignant tumors

Phase:

Phase 1

Details

Lead Sponsor:

Axelar AB

Treatments:

Podophyllotoxin